Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading Chinese pharmaceutical company, has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its nine-valent human papillomavirus (HPV) vaccine (Escherichia coli), specifically designed for the male population.
Global Impact and Vaccine Relevance
Globally, approximately 70,000 new cases of cancer in men each year are related to HPV infection, with the most common being penile cancer, anal cancer, oropharyngeal cancer, and other head and neck cancers. The vaccine covers seven high-risk HPV types (HPV16/18/31/33/45/52/58) and two low-risk types (HPV6/11), which are responsible for about 80% and 90% of these cancers, respectively.
Vaccine Efficacy and Indications
The nine-valent HPV vaccine is suitable for preventing genital warts caused by HPV6/11/16/18/31/33/45/52/58, as well as penile/perineal/perianal cancer and its precancerous lesions (grade 1, 2, 3 penile/perineal/perianal intraepithelial neoplasia, PIN1/2/3), anal cancer and its precancerous lesions (grade 1, 2, 3 anal intraepithelial neoplasia, AIN1/2/3), and other indications. This development marks a significant step forward in the prevention of HPV-related cancers and conditions in men.-Fineline Info & Tech
Leave a Reply